The combined predictive power of the atherogenic index of plasma and serum glycated albumin for cardiovascular events in postmenopausal patients with acute coronary syndrome after percutaneous coronary intervention.
Humans
Female
Percutaneous Coronary Intervention
/ adverse effects
Acute Coronary Syndrome
/ blood
Glycated Serum Albumin
Postmenopause
/ blood
Aged
Middle Aged
Serum Albumin
/ metabolism
Glycation End Products, Advanced
/ blood
Biomarkers
/ blood
Atherosclerosis
/ blood
Risk Factors
Myocardial Infarction
/ blood
Prognosis
Acute coronary syndrome
Atherogenic index of plasma
Menopause
Percutaneous coronary intervention
Serum glycated albumin
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
17
07
2024
accepted:
19
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Glycated Albumin (GA) and atherogenic index of plasma (AIP) are two important biomarkers that respectively reflect lipid and glucose levels. Previous research has revealed their roles in cardiovascular diseases (CVD) and diabetes. However, their combined predictive ability in forecasting cardiovascular events (CVE) after percutaneous coronary intervention (PCI) among postmenopausal acute coronary syndrome (ACS) patients remains insufficiently studied. Based on the levels of AIP (AIP-L and AIP-H) and GA (GA-L and GA-H), four groups were used to categorize the patients. The CVE assessed included cardiac death, nonfatal myocardial infarction (MI) and nonfatal stroke. To evaluate the relationship between AIP, GA, and CVE, multivariate Cox regression analyses were performed. 98 patients (7.5%) experienced CVE during follow-up. AIP and GA were revealed as strong independent predictors of CVE through multivariate analysis (AIP: HR 3.324, 95%CI 1.732-6.365, P = 0.004; GA: HR 1.098, 95% CI 1.023-1.177, P = 0.009). In comparison to those in the initial group (AIP-L and GA-L), the fourth group (AIP-H and GA-H) of patients exhibited the greatest CVE risk (HR 2.929, 95% CI 1.206-5.117, P = 0.018). Derived from the model of baseline risk, the combination of AIP + GA significantly enhanced the AUC, meanwhile combining AIP and GA levels maximized prognostic accuracy in the baseline risk model. This study found that the combined measurement of AIP and GA significantly enhanced the predictive capability for CVE following PCI in postmenopausal ACS patients. By integrating these two biomarkers, it became possible to more accurately identify high-risk individuals and provided clinicians with new predictive tools for postmenopausal ACS patients in risk assessment and management.
Sections du résumé
BACKGROUND
BACKGROUND
Glycated Albumin (GA) and atherogenic index of plasma (AIP) are two important biomarkers that respectively reflect lipid and glucose levels. Previous research has revealed their roles in cardiovascular diseases (CVD) and diabetes. However, their combined predictive ability in forecasting cardiovascular events (CVE) after percutaneous coronary intervention (PCI) among postmenopausal acute coronary syndrome (ACS) patients remains insufficiently studied.
METHODS
METHODS
Based on the levels of AIP (AIP-L and AIP-H) and GA (GA-L and GA-H), four groups were used to categorize the patients. The CVE assessed included cardiac death, nonfatal myocardial infarction (MI) and nonfatal stroke. To evaluate the relationship between AIP, GA, and CVE, multivariate Cox regression analyses were performed.
RESULTS
RESULTS
98 patients (7.5%) experienced CVE during follow-up. AIP and GA were revealed as strong independent predictors of CVE through multivariate analysis (AIP: HR 3.324, 95%CI 1.732-6.365, P = 0.004; GA: HR 1.098, 95% CI 1.023-1.177, P = 0.009). In comparison to those in the initial group (AIP-L and GA-L), the fourth group (AIP-H and GA-H) of patients exhibited the greatest CVE risk (HR 2.929, 95% CI 1.206-5.117, P = 0.018). Derived from the model of baseline risk, the combination of AIP + GA significantly enhanced the AUC, meanwhile combining AIP and GA levels maximized prognostic accuracy in the baseline risk model.
CONCLUSIONS
CONCLUSIONS
This study found that the combined measurement of AIP and GA significantly enhanced the predictive capability for CVE following PCI in postmenopausal ACS patients. By integrating these two biomarkers, it became possible to more accurately identify high-risk individuals and provided clinicians with new predictive tools for postmenopausal ACS patients in risk assessment and management.
Identifiants
pubmed: 39478539
doi: 10.1186/s12944-024-02335-2
pii: 10.1186/s12944-024-02335-2
doi:
Substances chimiques
Glycated Serum Albumin
0
Serum Albumin
0
Glycation End Products, Advanced
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
352Subventions
Organisme : China Scholarship Council
ID : 202308110233
Organisme : National Key Research and Development Program of China
ID : 2022YFC3602500
Organisme : Beijing Municipal Administration of Hospitals' Mission plan
ID : SML20180601
Organisme : Capital's Funds for Health Improvement and Research
ID : CFH 2020-2-2063
Organisme : Beijing Municipal Natural Science Foundation
ID : 7202041
Organisme : Beijing Hospitals Authority Youth Programme
ID : QML20210601
Organisme : National Natural Science Foundation of China
ID : 82300368
Informations de copyright
© 2024. The Author(s).
Références
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9 .
doi: 10.1016/S0140-6736(20)30925-9
van Roeters JE, Tokgözoğlu LS, Badimon L, Dumanski SM, Gulati M, Hess CN, et al. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European atherosclerosis society. Eur Heart J. 2023;44(39):4157–73. https://doi.org/10.1093/eurheartj/ehad472 .
doi: 10.1093/eurheartj/ehad472
Nansseu JR, Moor VJ, Nouaga ME, Zing-Awona B, Tchanana G, Ketcha A. Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women. Lipids Health Dis. 2016;15:49. https://doi.org/10.1186/s12944-016-0222-7 .
doi: 10.1186/s12944-016-0222-7
pubmed: 26957313
Manson JE, Woodruff TK. Reproductive Health as a marker of subsequent Cardiovascular Disease: the role of Estrogen. JAMA Cardiol. 2016;1(7):776–7. https://doi.org/10.1001/jamacardio.2016.2662 .
doi: 10.1001/jamacardio.2016.2662
pubmed: 27626902
North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19(3):257–71. https://doi.org/10.1097/gme.0b013e31824b970a .
doi: 10.1097/gme.0b013e31824b970a
Abdu FA, Alifu J, Mohammed AQ, Liu L, Zhang W, Yin G, et al. The correlation of atherogenic index of plasma with non-obstructive CAD and unfavorable prognosis among patients diagnosed with MINOCA. Eur J Intern Med Published Online March. 2024;26. https://doi.org/10.1016/j.ejim.2024.03.024 .
Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Dis. 2018;17(1):197. https://doi.org/10.1186/s12944-018-0828-z .
doi: 10.1186/s12944-018-0828-z
pubmed: 30134981
Guo Q, Zhou S, Feng X, Yang J, Qiao J, Zhao Y, et al. The sensibility of the new blood lipid indicator–atherogenic index of plasma (AIP) in menopausal women with coronary artery disease. Lipids Health Dis. 2020;19(1):27. https://doi.org/10.1186/s12944-020-01208-8 .
doi: 10.1186/s12944-020-01208-8
pubmed: 32093690
Liu Y, Feng X, Yang J, Zhai G, Zhang B, Guo Q, et al. The relation between atherogenic index of plasma and cardiovascular outcomes in prediabetic individuals with unstable angina pectoris. BMC Endocr Disord. 2023;23(1):187. https://doi.org/10.1186/s12902-023-01443-x .
doi: 10.1186/s12902-023-01443-x
pubmed: 37653411
Roohk HV, Zaidi AR, Patel D. Glycated albumin (GA) and inflammation: role of GA as a potential marker of inflammation. Inflamm Res. 2018;67(1):21–30. https://doi.org/10.1007/s00011-017-1089-4 .
doi: 10.1007/s00011-017-1089-4
pubmed: 29022053
Dozio E, Di Gaetano N, Findeisen P, Corsi Romanelli MM. Glycated albumin: from biochemistry and laboratory medicine to clinical practice. Endocrine. 2017;55(3):682–90. https://doi.org/10.1007/s12020-016-1091-6 .
doi: 10.1007/s12020-016-1091-6
pubmed: 27623968
Moon JH, Chae MK, Kim KJ, Kim HM, Cha BS, Lee HC, et al. Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease. Circ J. 2012;76(9):2273–9. https://doi.org/10.1253/circj.cj-11-1499 .
doi: 10.1253/circj.cj-11-1499
pubmed: 22664650
Liu C, Zhao Q, Ma X, Cheng Y, Sun Y, Zhang D, et al. Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21(1):11. https://doi.org/10.1186/s12933-022-01446-3 .
doi: 10.1186/s12933-022-01446-3
pubmed: 35045846
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826. https://doi.org/10.1093/eurheartj/ehad191 .
doi: 10.1093/eurheartj/ehad191
pubmed: 37622654
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19–40. https://doi.org/10.2337/dc23-S002 .
doi: 10.2337/dc23-S002
pubmed: 36507649
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. https://doi.org/10.1097/HJH.0000000000003480 .
doi: 10.1097/HJH.0000000000003480
pubmed: 37345492
Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apob-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583–8. https://doi.org/10.1016/s0009-9120(01)00263-6 .
doi: 10.1016/s0009-9120(01)00263-6
pubmed: 11738396
Mead GE, Sposato LA, Sampaio Silva G, Yperzeele L, Wu S, Kutlubaev M, et al. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. Int J Stroke. 2023;18(5):499–531. https://doi.org/10.1177/17474930231156753 .
doi: 10.1177/17474930231156753
pubmed: 36725717
Aydınyılmaz F, Özbeyaz NB, Guliyev İ, Algül E, Şahan HF, Kalkan K. Effect of Atherogenic Index of plasma on pre-percutaneous coronary intervention Thrombolysis in Myocardial Infarction Flow in patients with ST Elevation myocardial infarction. Angiol Published Online July. 2023;3. https://doi.org/10.1177/00033197231185204 .
Jiang Z, Zhu X, Zhao D, Jiang H, Wang X, Su F. Associations between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hyperuricemia: a cross-sectional study. Lipids Health Dis. 2024;23(1):280. https://doi.org/10.1186/s12944-024-02269-9 .
doi: 10.1186/s12944-024-02269-9
pubmed: 39227876
Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184–223. https://doi.org/10.3390/ijms15046184 .
doi: 10.3390/ijms15046184
pubmed: 24733068
Chen B, Zeng J, Fan M, You Q, Wang C, Wang K, et al. A longitudinal study on the impact of the TyG Index and TG/HDL-C ratio on the risk of type 2 diabetes in Chinese patients with prediabetes. Lipids Health Dis. 2024;23(1):262. https://doi.org/10.1186/s12944-024-02239-1 .
doi: 10.1186/s12944-024-02239-1
pubmed: 39175004
Graham A. Modulation of the Cellular microRNA Landscape: contribution to the Protective effects of high-density lipoproteins (HDL). Biology (Basel). 2023;12(9):1232. https://doi.org/10.3390/biology12091232 .
doi: 10.3390/biology12091232
pubmed: 37759631
Kurklu HA, Tan TS, Ozyuncu N, Baskovski E, Ozdol C. Atherogenic index of plasma predicts obstructive coronary artery disease in patients with stable angina Pectoris. Diagnostics (Basel). 2023;13(20):3249. https://doi.org/10.3390/diagnostics13203249 .
doi: 10.3390/diagnostics13203249
pubmed: 37892070
Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2(4):279–88. https://doi.org/10.1016/S2213-8587(13)70199-2 .
doi: 10.1016/S2213-8587(13)70199-2
pubmed: 24703046
Traldi P, Castilho G, Sartori CH, Machado-Lima A, Nakandakare ER, Corrêa-Giannella ML, et al. Glycated human serum albumin isolated from poorly controlled diabetic patients impairs cholesterol efflux from macrophages: an investigation by mass spectrometry. Eur J Mass Spectrom (Chichester). 2015;21(3):233–44. https://doi.org/10.1255/ejms.1322 .
doi: 10.1255/ejms.1322
pubmed: 26307703
Machado-Lima A, López-Díez R, Iborra RT, Pinto RS, Daffu G, Shen X, et al. RAGE mediates cholesterol efflux impairment in Macrophages caused by Human Advanced Glycated Albumin. Int J Mol Sci. 2020;21(19):7265. https://doi.org/10.3390/ijms21197265 .
doi: 10.3390/ijms21197265
pubmed: 33019603
Minanni CA, Machado-Lima A, Iborra RT, Okuda LS, de Souza Pinto R, Santana MFM, et al. Persistent effect of Advanced Glycated Albumin driving inflammation and disturbances in cholesterol efflux in macrophages. Nutrients. 2021;13(10):3633. https://doi.org/10.3390/nu13103633 .
doi: 10.3390/nu13103633
pubmed: 34684632
Gomes DJ, Velosa AP, Okuda LS, Fusco FB, da Silva KS, Pinto PR, et al. Glycated albumin induces lipid infiltration in mice aorta independently of DM and RAS local modulation by inducing lipid peroxidation and inflammation. J Diabetes Complications. 2016;30(8):1614–21. https://doi.org/10.1016/j.jdiacomp.2016.07.001 .
doi: 10.1016/j.jdiacomp.2016.07.001
pubmed: 27440461
Noels H, Jankowski V, Schunk SJ, Vanholder R, Kalim S, Jankowski J. Post-translational modifications in kidney diseases and associated cardiovascular risk. Nat Rev Nephrol. 2024;20(8):495–512. https://doi.org/10.1038/s41581-024-00837-x .
doi: 10.1038/s41581-024-00837-x
pubmed: 38664592
Copur S, Siriopol D, Afsar B, Comert MC, Uzunkopru G, Sag AA, et al. Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. Acta Diabetol. 2021;58(1):81–91. https://doi.org/10.1007/s00592-020-01581-x .
doi: 10.1007/s00592-020-01581-x
pubmed: 32862262
Belinskaia DA, Voronina PA, Shmurak VI, Jenkins RO, Goncharov NV. Serum albumin in Health and Disease: esterase, antioxidant, Transporting and Signaling properties. Int J Mol Sci. 2021;22(19):10318. https://doi.org/10.3390/ijms221910318 .
doi: 10.3390/ijms221910318
pubmed: 34638659
Blache D, Bourdon E, Salloignon P, Lucchi G, Ducoroy P, Petit JM, et al. Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes. Diabetes. 2015;64(3):960–72. https://doi.org/10.2337/db14-0879 .
doi: 10.2337/db14-0879
pubmed: 25157094
Jujic A, Engström G, Nilsson PM, Johansson M. Accumulation of advanced glycation end products in skin and increased vascular ageing in the general population: the Malmö offspring study. J Hypertens. 2024;42(3):530–7. https://doi.org/10.1097/HJH.0000000000003627 .
doi: 10.1097/HJH.0000000000003627
pubmed: 38088420
Lu H, Xu S, Liang X, Dai Y, Huang Z, Ren Y, et al. Advanced Glycated End products Alter Neutrophil Effect on Regulation of CD4 + T cell differentiation through induction of myeloperoxidase and neutrophil elastase activities. Inflammation. 2019;42(2):559–71. https://doi.org/10.1007/s10753-018-0913-5 .
doi: 10.1007/s10753-018-0913-5
pubmed: 30343390
Huang X, Wen S, Huang Y, Huang Z. Gender differences in the association between changes in the atherogenic index of plasma and cardiometabolic diseases: a cohort study. Lipids Health Dis. 2024;23(1):135. https://doi.org/10.1186/s12944-024-02117-w .
doi: 10.1186/s12944-024-02117-w
pubmed: 38715126
Zhang Y, Wu S, Tian X, Xu Q, Xia X, Zhang X, et al. Elevated atherogenic index of plasma increased the risk of myocardial infarction in a general population. Ann Epidemiol. 2024;90:1–8. https://doi.org/10.1016/j.annepidem.2023.11.002 .
doi: 10.1016/j.annepidem.2023.11.002
pubmed: 37979893
Zhu Y, Chen M, Liu K, Gao A, Kong X, Liu Y, et al. Atherogenic Index of Plasma and the risk of In-Stent restenosis in patients with Acute Coronary Syndrome beyond the traditional risk factors. J Atheroscler Thromb. 2022;29(8):1226–35. https://doi.org/10.5551/jat.63136 .
doi: 10.5551/jat.63136
pubmed: 34497172
Zhang Y, Chen S, Tian X, Xu Q, Xia X, Zhang X, et al. Elevated atherogenic index of plasma associated with stroke risk in general Chinese. Endocr Published Online January. 2024;10. https://doi.org/10.1007/s12020-023-03677-0 .
He Y, Li Z, Yu L, Liu Y, Li L, Yang R, et al. Association between the atherogenic index of plasma and carotid artery plaques in patients with coronary heart disease in different glucose metabolism states: an RCSCD-TCM study in Tianjin, China. Endocrine. 2023;81(2):252–61. https://doi.org/10.1007/s12020-023-03389-5 .
doi: 10.1007/s12020-023-03389-5
pubmed: 37231238
Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic index of plasma: Novel Predictive Biomarker for Cardiovascular illnesses. Arch Med Res. 2019;50(5):285–94. https://doi.org/10.1016/j.arcmed.2019.08.009 .
doi: 10.1016/j.arcmed.2019.08.009
pubmed: 31593853
Bendzala M, Sabaka P, Caprnda M, Komornikova A, Bisahova M, Baneszova R, et al. Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women: a 10-year follow-up. Wien Klin Wochenschr. 2017;129(21–22):793–8. https://doi.org/10.1007/s00508-017-1264-1 .
doi: 10.1007/s00508-017-1264-1
pubmed: 28913629
Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M, et al. Fructosamine and Glycated Albumin and the risk of Cardiovascular outcomes and Death. Circulation. 2015;132(4):269–77. https://doi.org/10.1161/CIRCULATIONAHA.115.015415 .
doi: 10.1161/CIRCULATIONAHA.115.015415
pubmed: 26022911
Yang ZK, Shen Y, Shen WF, Pu LJ, Meng H, Zhang RY, et al. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. Int J Cardiol. 2015;197:241–7. https://doi.org/10.1016/j.ijcard.2015.06.003 .
doi: 10.1016/j.ijcard.2015.06.003
pubmed: 26142969
Mihara A, Ohara T, Hata J, Honda T, Chen S, Sakata S, et al. Association between serum glycated albumin and risk of cardiovascular disease in a Japanese community: the Hisayama Study. Atherosclerosis. 2020;311:52–9. https://doi.org/10.1016/j.atherosclerosis.2020.08.016 .
doi: 10.1016/j.atherosclerosis.2020.08.016
pubmed: 32942084
Zhang J, Du Y, Hu C, Liu Y, Liu J, Gao A, et al. Elevated glycated albumin in serum is Associated with adverse cardiac outcomes in patients with Acute Coronary Syndrome who underwent revascularization therapy. J Atheroscler Thromb. 2022;29(4):482–91. https://doi.org/10.5551/jat.61358 .
doi: 10.5551/jat.61358
pubmed: 33642440
Jiang L, Li L, Xu Z, Tang Y, Zhai Y, Fu X, et al. Non-linear associations of atherogenic index of plasma with prediabetes and type 2 diabetes mellitus among Chinese adults aged 45 years and above: a cross-sectional study from CHARLS. Front Endocrinol (Lausanne). 2024;15:1360874. https://doi.org/10.3389/fendo.2024.1360874 .
doi: 10.3389/fendo.2024.1360874
pubmed: 38628590
Zheng X, Zhang X, Han Y, Hu H, Cao C. Nonlinear relationship between atherogenic index of plasma and the risk of prediabetes: a retrospective study based on Chinese adults. Cardiovasc Diabetol. 2023;22(1):205. https://doi.org/10.1186/s12933-023-01934-0 .
doi: 10.1186/s12933-023-01934-0
pubmed: 37563588
Zendjabil M. Glycated albumin. Clin Chim Acta. 2020;502:240–4. https://doi.org/10.1016/j.cca.2019.11.007 .
doi: 10.1016/j.cca.2019.11.007
pubmed: 31734145
Nathan DM, McGee P, Steffes MW, Lachin JM, DCCT/EDIC Research Group. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63(1):282–90. https://doi.org/10.2337/db13-0782 .
doi: 10.2337/db13-0782
pubmed: 23990364